Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. reports clinical, regulatory and financial developments for a clinical-stage biotechnology business developing oncolytic immunotherapies for cancer. The company’s proprietary RPx platform uses an engineered HSV-1 backbone intended to promote tumor cell killing, immunogenic cell death and systemic anti-tumor immune responses.
Recurring Replimune news centers on RP1, or vusolimogene oderparepvec, including data from the IGNYTE clinical trial, combination use with nivolumab in advanced melanoma, Biologics License Application activity and FDA complete response letters. Updates also cover RP2 clinical data in advanced solid tumors, scientific presentations at oncology meetings, quarterly financial results, research and development spending, cash runway commentary and management presentations at healthcare conferences.
Replimune Group, Inc. (NASDAQ: REPL) reached its target enrollment of 180 patients for the CERPASS trial, evaluating RP1 in cutaneous squamous cell carcinoma (CSCC). Primary analysis data is expected in H1 2023. The initial cohort of 75 patients for the IGNYTE trial, assessing RP1 with Opdivo in anti-PD1 failed melanoma, has been enrolled, with data to be reported in Q4 2022. Financially, Replimune reported a net loss of $42.3 million for Q1 2022, an increase from $27.3 million in Q1 2021, with R&D expenses rising due to clinical advancements and personnel costs.
Replimune Group, a clinical stage biotechnology company specializing in tumor-directed oncolytic immunotherapies, announced its participation in two upcoming investor conferences. The BTIG Biotechnology Conference will take place on August 8, 2022, featuring a fireside chat at 11:00 am ET. The company will also present at the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, with a fireside chat scheduled for 9:45 am ET. A live webcast will be available on Replimune's website.
Replimune Group (NASDAQ: REPL) announced the resignation of Jason Rhodes from its Board of Directors, effective June 3, 2022. Rhodes, a partner at Atlas Venture, served on the board since 2015 and was key during the company's Series A financing. His departure is attributed to increased commitments at Atlas Venture, including a new fund launch. CEO Philip Astley-Sparke expressed gratitude for Rhodes' contributions and highlighted the company's ongoing focus on oncolytic immunotherapies, anticipating significant data releases in the next 12 months.
Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, will present at the Jefferies Healthcare Conference on June 9, 2022, at 9:30 AM ET. The event will be held at Marriott Marquis in New York. Founded in 2015, Replimune focuses on innovating tumor-directed oncolytic immunotherapies using its proprietary RPx platform. This platform utilizes an HSV-1 backbone to enhance immune responses against tumors while maintaining a strong safety profile. For more details, visit www.replimune.com.
Replimune Group, a clinical-stage biotechnology firm, presented key updates on its ongoing trials at the 2022 ASCO Annual Meeting from June 3-7, in Chicago.
Highlights include:
- RP1 results from the IGNYTE study, combining RP1 with Opdivo.
- Ongoing trials for RP2 and RP3 programs.
The CERPASS trial aims to evaluate treatment efficacy in advanced cutaneous squamous cell carcinoma, enrolling 180 patients. This study represents a significant step in Replimune's mission to innovate cancer therapies.
Replimune Group, Inc. reported financial results for the fiscal year ending March 31, 2022, indicating a net loss of $118.0 million, up from $80.9 million the previous year. Total research and development expenses reached $79.5 million, an increase from $56.8 million, largely due to expanding clinical trials. The company has a strong cash position of $395.7 million which it believes will fund operations into the second half of 2024. Enrollment in key clinical trials is ongoing, with top line data from significant trials expected in late 2022 and early 2023.
Replimune Group (NASDAQ: REPL) announced promising updates from its Phase 2 IGNYTE trial focusing on RP1, its oncolytic immunotherapy, for melanoma and non-melanoma skin cancers. Initial data reveals that RP1 combined with Opdivo continues to yield deep and durable responses, particularly in anti-PD1 failed patients. New data for RP1 as monotherapy in solid organ transplant recipients shows early clinical activity. The company has announced a broad Phase 2 development plan for RP2/RP3 targeting hard-to-treat tumors, emphasizing its commitment to addressing significant unmet medical needs in oncology.
Replimune Group Inc. (NASDAQ: REPL) will host an investor event on March 30, 2022, at 8:00 AM ET to present updated data from its Phase 2 IGNYTE clinical trial in non-melanoma skin cancer and melanoma. New data from the ongoing trial in anti-PD1 failed NMSC will also be shared, alongside findings from the ARTACUS clinical trial involving RP1 as monotherapy for solid organ transplant recipients with skin cancer. The event will be accessible via live webcast on Replimune's website, with a replay available post-event.
Replimune Group, a clinical stage biotechnology company, announced that CEO Philip Astley-Sparke will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 8:40 AM ET. The event will take place virtually, and a webcast will be accessible on Replimune's website, with a replay available for 90 days post-conference. Replimune specializes in developing tumor-directed oncolytic immunotherapies using its proprietary RPx platform, aiming to enhance cancer treatment through innovative mechanisms.
Replimune Group Inc. (NASDAQ: REPL) reported its financial results for the third fiscal quarter ended December 31, 2021, revealing a net loss of $29.7 million, up from $21.8 million a year ago. Research and development expenses rose to $19.4 million, reflecting heightened clinical activities. The company holds $420.2 million in cash, expected to fund operations until mid-2024. Upcoming milestones include initial data releases from various clinical trials and an investor event in March 2022 to discuss commercial strategies and RP2/3 development plans.